Previous work has established that the effects of mutated CBL and mutated FLT3 on intracellular signalling, particularly transforming hyperstimulation of signalling molecules downstream of FLT3, are similar,12 and we thus sought to comprehensively evaluate clinical‐grade inhibitors of FLT3 for efficacy against mutant CBL AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.